



## Author index

### Volume 258 (1997)

- Adachi, J., see Miwa, A. 258, 125  
Amigo, L., see Greco, A.V. 258, 209  
Arapinis, C., S. Kostaridou, C. Kattamis, Effective detection of active HCV infection: HCV RNA carrier state in a context free of hepatitis symptoms 258, 91  
Beijering, R.J.R., C.H. Gips, J.R. Huizenga, J. Jager, A.J. Mackor, H. Salomons, E. Knol, T.H. Lijnema, Whole blood and plasma water in health and disease: longitudinal and transverse observations and correlations with several different hematological and clinico-chemical parameters 258, 59  
Biggs, H.G., see Doumas, B.T. 258, 21  
Bousser, F., see Kutter, D. 258, 231  
Carbone, V., see Corso, G. 258, 193  
Castagneto, M., see Greco, A.V. 258, 209  
Chetty, N., N.H. Naran, A.R.P. Walker, H.C. Seftel, B.I. Joffe, F.J. Raal, Plasma fatty acid levels in South African interethnic male high school pupils at different ultimate risks of coronary heart disease 258, 31  
Christensen, L., see Høgdall, C.K. 258, 159  
Christiansen, M., see Høgdall, C.K. 258, 159  
Clemmensen, I., see Høgdall, C.K. 258, 159  
Cooreman, M.P., see Mulder, T.P.J. 258, 69  
Corso, G., E. Trivellone, A. Motta, A. Postiglione, F.P. Mancini, V. Carbone, C. Napoli, Effect of low density lipoprotein fatty acid composition on copper-induced peroxidation: <sup>1</sup>H-nuclear magnetic resonance analysis 258, 193  
Couderc, R., see Lefèvre, G. 258, 249  
de Bruin, W.C.C., see Mulder, T.P.J. 258, 69  
De Gaetano, A., see Greco, A.V. 258, 209  
Demirel, M., see Haklar, G. 258, 201  
de Vries, I.H., see Janssens, P.M.W. 258, 179  
Doumas, B.T., T. Peters, Jr., Serum and urine albumin: a progress report on their measurement and clinical significance 258, 3  
Doumas, B.T., W.A. Watson, H.G. Biggs, Albumin standards and the measurement of serum albumin with bromocresol green 258, 21  
Dullaart, R.P.F., see Riemens, S.C. 258, 105  
Eskitürk, A., see Haklar, G. 258, 201  
Evans, K., J. Mitcheson, M.F. Laker, Effect of storage at -70°C on lipid, lipoprotein and apolipoprotein concentrations 258, 219  
Gips, C.H., see Beijering, R.J.R. 258, 59  
Greco, A.V., G. Mingrone, A. De Gaetano, L. Amigo, L. Puglielli, M. Castagneto, F. Nervi, Uptake of dodecanedioic acid by isolated rat liver 258, 209  
Haklar, G., M. Demirel, Ö. Peker, A. Eskitürk, A. İşgör, G. Söyletir, A.S. Yalçın, The functional assessment of autotransplanted splenic tissue by its capacity to remove oxidatively modified erythrocytes 258, 201  
Høgdall, C.K., M. Christiansen, L. Christensen, A.K. Yazova, C. Koch, I. Clemmensen, B. Nørgaard-Pedersen, Monoclonal antibodies against human tetranectin, epitope characterization and use in immunohistochemistry 258, 159  
Higashi, K., see Shige, H. 258, 145  
Hirohata, S., see Kajikawa, Y. 258, 241  
Hötl, W., see Vogl, M. 258, 79  
Hoogenberg, K., see Riemens, S.C. 258, 105

- Huizenga, J.R., see Beijering, R.J.R. 258, 59  
Huseby, N.-E., see Mortensen, B. 258, 47
- Ikwaki, K., see Shige, H. 258, 145  
İsgör, A., see Haklar, G. 258, 201  
Ishikawa, T., see Shige, H. 258, 145
- Jager, J., see Beijering, R.J.R. 258, 59  
Jansen, J.B.M.J., see Mulder, T.P.J. 258, 69  
Janssens, A.R., see Mulder, T.P.J. 258, 69  
Janssens, P.M.W., S. Kuiper, I.H. de Vries, J.L. Willems, I. Klasen, M. van Oosterwijk, J. Paardekooper, Coating in vitro of erythrocytes with Tamm Horsfall-Protein 258, 179  
Joffe, B.I., see Chetty, N. 258, 31
- Kajikawa, Y., S. Kusachi, J. Kondo, I. Sano, K. Yamamoto, S. Hirohata, M. Murakami, T. Murakami, T. Tsuji, Time-dependent alterations of serum levels of triple-helix domain and 7S domain of type IV collagen in patients with acute myocardial infarction after successful reperfusion: limited relation to left ventricular ejection fraction 258, 241  
Kambris, Z., see Kutter, D. 258, 231  
Kattamis, C., see Arapinis, C. 258, 91  
Klasen, I., see Janssens, P.M.W. 258, 179  
Knol, E., see Beijering, R.J.R. 258, 59  
Koch, C., see Høgdall, C.K. 258, 159  
Kondo, J., see Kajikawa, Y. 258, 241  
Kostaridou, S., see Arapinis, C. 258, 91  
Kremer, A., see Kutter, D. 258, 231  
Kuiper, S., see Janssens, P.M.W. 258, 179  
Kusachi, S., see Kajikawa, Y. 258, 241  
Kutter, D., A. Kremer, F. Bousser, Z. Kambris, A simple and inexpensive screening test for low protein levels in urine 258, 231
- Laker, M.F., see Evans, K. 258, 219  
Lefèvre, G., I. Myara, J. Peynet, R. Couderc, G. Section Lipoprotéines, Effect of sucrose/–80°C storage of plasma on between-site values of low-density lipoprotein susceptibility to copper-induced oxidation 258, 249  
Lijnema, T.H., see Beijering, R.J.R. 258, 59
- Mackor, A.J., see Beijering, R.J.R. 258, 59  
Mancini, F.P., see Corso, G. 258, 193  
Mingrone, G., see Greco, A.V. 258, 209  
Mitcheson, J., see Evans, K. 258, 219  
Miwa, A., J. Adachi, K. Mizuno, Y. Tatsuno, Very long-chain fatty acid pattern in crush syndrome patients in the Kobe Earthquake 258, 125  
Mizuno, K., see Miwa, A. 258, 125  
Mortensen, B., N.-E. Huseby, Clearance of circulating  $\gamma$ -glutamyltransferase by the asialoglycoprotein receptor. Enzyme forms with different sialic acid content are eliminated at different clearance rates and without apparent desialylation 258, 47  
Moss, D., M. Werner, Forty years of Clinica Chimica Acta 258, 1  
Motta, A., see Corso, G. 258, 193  
Mulder, T.P.J., A.R. Janssens, W.C.C. de Bruin, W.H.M. Peters, M.P. Cooreman, J.B.M.J. Jansen, Plasma glutathione S-transferase alfa-1 levels in patients with chronic liver disorders 258, 69  
Müller, M.M., see Vogl, M. 258, 79  
Murakami, M., see Kajikawa, Y. 258, 241  
Murakami, T., see Kajikawa, Y. 258, 241  
Myara, I., see Lefèvre, G. 258, 249
- Nagai, T., see Okazaki, T. 258, 137  
Nakajima, K., see Shige, H. 258, 145  
Nakamura, H., see Shige, H. 258, 145  
Napoli, C., see Corso, G. 258, 193  
Naran, N.H., see Chetty, N. 258, 31  
Nervi, F., see Greco, A.V. 258, 209  
Nishiwaki, M., see Shige, H. 258, 145  
Nørgaard-Pedersen, B., see Høgdall, C.K. 258, 159
- Okazaki, T., Y. Yanagisawa, T. Nagai, Analysis of the affinity of each haptoglobin polymer for hemoglobin by two-dimensional affinity electrophoresis 258, 137
- Paardekooper, J., see Janssens, P.M.W. 258, 179  
Peker, Ö., see Haklar, G. 258, 201  
Peters, T., Jr., see Doumas, B.T. 258, 3  
Peters, W.H.M., see Mulder, T.P.J. 258, 69  
Peynet, J., see Lefèvre, G. 258, 249  
Postiglione, A., see Corso, G. 258, 193  
Puglielli, L., see Greco, A.V. 258, 209
- Raal, F.J., see Chetty, N. 258, 31  
Riemens, S.C., A. van Tol, K. Hoogenberg, T. van Gent, L.M. Scheek, W.J. Sluiter, R.P.F. Dullaart, Higher high density lipoprotein cholesterol associated with moderate alcohol consumption is not related to altered plasma lecithin:cholesterol acyltransferase and lipid transfer protein activity levels 258, 105
- Salomons, H., see Beijering, R.J.R. 258, 59  
Sano, I., see Kajikawa, Y. 258, 241

- Scheek, L.M., see Riemens, S.C. 258, 105  
 Section Lipoprotéines, G., see Lefèvre, G. 258, 249  
 Seftel, H.C., see Chetty, N. 258, 31  
 Shige, H., T. Ishikawa, K. Ikewaki, M. Nishiwaki, K. Higashi, K. Nakajima, H. Nakamura, Remnant-like very-low-density lipoprotein isolated from hypertriglyceridemic patients by immunoaffinity chromatography suppressed 3-hydroxy-3-methylglutaryl coenzyme A activity of cultured human skin fibroblasts 258, 145  
 Sluiter, W.J., see Riemens, S.C. 258, 105  
 Söyletir, G., see Haklar, G. 258, 201  
 Tatsuno, Y., see Miwa, A. 258, 125  
 Trivellone, E., see Corso, G. 258, 193  
 Tsuji, T., see Kajikawa, Y. 258, 241  
 van Gent, T., see Riemens, S.C. 258, 105  
 van Oosterwijk, M., see Janssens, P.M.W. 258, 179  
 van Tol, A., see Riemens, S.C. 258, 105  
 Vogl, M., M.M. Müller, W. Hörtl, Clinical usefulness of percentage of free serum prostate specific antigen 258, 79  
 Walker, A.R.P., see Chetty, N. 258, 31  
 Watson, W.A., see Doumas, B.T. 258, 21  
 Werner, M., see Moss, D. 258, 1  
 Willems, J.L., see Janssens, P.M.W. 258, 179  
 Yalçin, A.S., see Haklar, G. 258, 201  
 Yamamoto, K., see Kajikawa, Y. 258, 241  
 Yanagisawa, Y., see Okazaki, T. 258, 137  
 Yazova, A.K., see Hogdall, C.K. 258, 159



## Subject index

### Volume 258 (1997)

- Alcohol:** High density lipoproteins; Lecithin: cholesterol acyltransferase; Cholesteryl ester transfer protein; Phospholipid transfer protein 258, 105
- Alcoholic liver cirrhosis:** Glutathione S-transferase alpha; Enzyme immunoassay; Primary biliary cirrhosis; Primary sclerosing cholangitis; Chronic hepatitis B 258, 69
- Antioxidants:** Atherosclerosis; Lipid peroxidation; Diene production 258, 249
- Asialoglycoprotein receptor:**  $\gamma$ -Glutamyltransferase; Sialic acid; Serum glycoproteins; Clearance 258, 47
- Asymptomatic, anti-HCV<sup>+</sup> HCV carrier:** Non-A, non-B hepatitis (NANB); Hepatitis C virus (HCV) 258, 91
- Atherosclerosis:** Antioxidants; Lipid peroxidation; Diene production 258, 249
- Bromocresol green:** Serum albumin; Urinary albumin; Measurement; Bromocresol purple 258, 3
- Bromocresol purple:** Serum albumin; Urinary albumin; Measurement; Bromocresol green 258, 3
- Carbonyl content:** Heinz body; Splenic auto-transplantation; Thiobarbituric acid reactive substances 258, 201
- Cholesterol:** Triglycerides; Phospholipids; Sample handling; Variation, source of 258, 219
- Cholesteryl ester transfer protein:** High density lipoproteins; Alcohol; Lecithin:cholesterol acyltransferase; Phospholipid transfer protein 258, 105
- Chronic hepatitis B:** Glutathione S-transferase alpha; Enzyme immunoassay; Alcoholic liver cirrhosis; Primary biliary cirrhosis; Primary sclerosing cholangitis 258, 69
- Clearance:**  $\gamma$ -Glutamyltransferase; Asialoglycoprotein receptor; Sialic acid; Serum glycoproteins 258, 47
- Coronary heart disease:** Dietary fat intake; Plasma cholesterol; Plasma fatty acids 258, 31
- Crush syndrome:** Very long-chain fatty acids; Hexacosanoic acid; Hexacosenoic acid; Earthquake; Erythrocyte 258, 125
- Dicarboxylic acid:** Dodecanedioic acid; HPLC; Isolated liver perfusion; Mathematical models 258, 209
- Diene production:** Atherosclerosis; Antioxidants; Lipid peroxidation 258, 249
- Dietary fat intake:** Coronary heart disease; Plasma cholesterol; Plasma fatty acids 258, 31
- Disease:** Whole blood water; Plasma water; Hematological and clinicochemical parameters; Health 258, 59

- Dodecanedioic acid**; Dicarboxylic acid; HPLC; Isolated liver perfusion; Mathematical models 258, 209
- Earthquake**; Crush syndrome; Very long-chain fatty acids; Hexacosanoic acid; Hexacosenoic acid; Erythrocyte 258, 125
- Enzyme immunoassay**; Glutathione *S*-transferase alpha; Alcoholic liver cirrhosis; Primary biliary cirrhosis; Primary sclerosing cholangitis; Chronic hepatitis B 258, 69
- Epitope**; Human tetranectin; Monoclonal antibody; Immunohistochemistry 258, 159
- Erythrocyte**; Crush syndrome; Very long-chain fatty acids; Hexacosanoic acid; Hexacosenoic acid; Earthquake 258, 125
- Erythrocytes**; Tamm Horsfall protein; In vitro coating 258, 179
- Extracellular matrix**; Left ventriculography; Ventricular remodeling; Ischemic heart disease; Immunoassay; Ventricular function 258, 241
- $\gamma$ -Glutamyltransferase**; Asialoglycoprotein receptor; Sialic acid; Serum glycoproteins; Clearance 258, 47
- Glutathione *S*-transferase alpha**; Enzyme immunoassay; Alcoholic liver cirrhosis; Primary biliary cirrhosis; Primary sclerosing cholangitis; Chronic hepatitis B 258, 69
- Haptoglobin**; Hemoglobin; Two-dimensional affinity electrophoresis 258, 137
- Health**; Whole blood water; Plasma water; Hematological and clinicochemical parameters; Disease 258, 59
- Heinz body**; Carbonyl content; Splenic auto-transplantation; Thiobarbituric acid reactive substances 258, 201
- Hematological and clinicochemical parameters**; Whole blood water; Plasma water; Health; Disease 258, 59
- Hemoglobin**; Haptoglobin; Two-dimensional affinity electrophoresis 258, 137
- Hepatitis C virus (HCV)**; Non-A, non-B hepatitis (NANB); Asymptomatic, anti-HCV - HCV carrier 258, 91
- Hexacosanoic acid**; Crush syndrome; Very long-chain fatty acids; Hexacosenoic acid; Earthquake; Erythrocyte 258, 125
- Hexacosenoic acid**; Crush syndrome; Very long-chain fatty acids; Hexacosanoic acid; Earthquake; Erythrocyte 258, 125
- High density lipoproteins**; Alcohol; Lecithin:cholesterol acyltransferase; Cholesteryl ester transfer protein; Phospholipid transfer protein 258, 105
- HMG CoA reductase activity**; Immunoaffinity chromatography; Remnant VLDL; Hypertriglyceridemia 258, 145
- HPLC**; Dodecanedioic acid; Dicarboxylic acid; Isolated liver perfusion; Mathematical models 258, 209
- Human tetranectin**; Monoclonal antibody; Epitope; Immunohistochemistry 258, 159
- Hypertriglyceridemia**; Immunoaffinity chromatography; Remnant VLDL; HMG CoA reductase activity 258, 145
- Immunoaffinity chromatography**; Remnant VLDL; Hypertriglyceridemia; HMG CoA reductase activity 258, 145
- Immunoassay**; Left ventriculography; Ventricular remodeling; Ischemic heart disease; Extracellular matrix; Ventricular function 258, 241
- Immunohistochemistry**; Human tetranectin; Monoclonal antibody; Epitope 258, 159
- In vitro coating**; Erythrocytes; Tamm Horsfall protein 258, 179
- Ischemic heart disease**; Left ventriculography; Ventricular remodeling; Extracellular matrix; Immunoassay; Ventricular function 258, 241
- Isolated liver perfusion**; Dodecanedioic acid; Dicarboxylic acid; HPLC; Mathematical models 258, 209

- LDL**; NMR; Oleic acid; Peroxidation; Oxygen radicals 258, 193
- Lecithin:cholesterol acyltransferase**; High density lipoproteins; Alcohol; Cholesteryl ester transfer protein; Phospholipid transfer protein 258, 105
- Left ventriculography**; Ventricular remodeling; Ischemic heart disease; Extracellular matrix; Immunoassay; Ventricular function 258, 241
- Lipid peroxidation**; Atherosclerosis; Anti-oxidants; Diene production 258, 249
- Mathematical models**; Dodecanedioic acid; Dicarboxylic acid; HPLC; Isolated liver perfusion 258, 209
- Measurement**; Serum albumin; Urinary albumin; Bromocresol green; Bromocresol purple 258, 3
- Monoclonal antibody**; Human tetranectin; Epitope; Immunohistochemistry 258, 159
- Nigrosin**; Screening test; Proteins; Urine 258, 231
- NMR**; LDL; Oleic acid; Peroxidation; Oxygen radicals 258, 193
- Non-A, non-B hepatitis (NANB)**; Hepatitis C virus (HCV); Asymptomatic, anti-HCV-HCV carrier 258, 91
- Oleic acid**; LDL; NMR; Peroxidation; Oxygen radicals 258, 193
- Oxygen radicals**; LDL; NMR; Oleic acid; Peroxidation 258, 193
- Percentage of free prostate specific antigen**; Total prostate specific antigen; Prostate cancer screening 258, 79
- Peroxidation**; LDL; NMR; Oleic acid; Oxygen radicals 258, 193
- Phospholipids**; Cholesterol; Triglycerides; Sample handling; Variation, source of 258, 219
- Phospholipid transfer protein**; High density lipoproteins; Alcohol; Lecithin:cholesterol acyltransferase; Cholesteryl ester transfer protein 258, 105
- Plasma cholesterol**; Coronary heart disease; Dietary fat intake; Plasma fatty acids 258, 31
- Plasma fatty acids**; Coronary heart disease; Dietary fat intake; Plasma cholesterol 258, 31
- Plasma water**; Whole blood water; Hematological and clinicochemical parameters; Health; Disease 258, 59
- Primary biliary cirrhosis**; Glutathione S-transferase alpha; Enzyme immunoassay; Alcoholic liver cirrhosis; Primary sclerosing cholangitis; Chronic hepatitis B 258, 69
- Primary sclerosing cholangitis**; Glutathione S-transferase alpha; Enzyme immunoassay; Alcoholic liver cirrhosis; Primary biliary cirrhosis; Chronic hepatitis B 258, 69
- Prostate cancer screening**; Total prostate specific antigen; Percentage of free prostate specific antigen 258, 79
- Proteins**; Screening test; Urine; Nigrosin 258, 231
- Remnant VLDL**; Immunoaffinity chromatography; Hypertriglyceridemia; HMG CoA reductase activity 258, 145
- Sample handling**; Cholesterol; Triglycerides; Phospholipids; Variation, source of 258, 219
- Screening test**; Proteins; Urine; Nigrosin 258, 231
- Serum albumin**; Urinary albumin; Measurement; Bromocresol green; Bromocresol purple 258, 3
- Serum glycoproteins**;  $\gamma$ -Glutamyltransferase; Asialoglycoprotein receptor; Sialic acid; Clearance 258, 47
- Sialic acid**;  $\gamma$ -Glutamyltransferase; Asialoglycoprotein receptor; Serum glycoproteins; Clearance 258, 47
- Splenic autotransplantation**; Carbonyl content; Heinz body; Thiobarbituric acid reactive substances 258, 201

- Tamm Horsfall protein;** Erythrocytes; In vitro coating **258**, 179
- Thiobarbituric acid reactive substances;** Carbonyl content; Heinz body; Splenic autotransplantation **258**, 201
- Total prostate specific antigen;** Percentage of free prostate specific antigen; Prostate cancer screening **258**, 79
- Triglycerides;** Cholesterol; Phospholipids; Sample handling; Variation, source of **258**, 219
- Two-dimensional affinity electrophoresis;** Haptoglobin; Hemoglobin **258**, 137
- Urinary albumin;** Serum albumin; Measurement; Bromocresol green; Bromocresol purple **258**, 3
- Urine;** Screening test; Proteins; Nigrosin **258**, 231
- Variation, source of;** Cholesterol; Triglycerides; Phospholipids; Sample handling **258**, 219
- Ventricular function;** Left ventriculography; Ventricular remodeling; Ischemic heart disease; Extracellular matrix; Immunoassay **258**, 241
- Ventricular remodeling;** Left ventriculography; Ischemic heart disease; Extracellular matrix; Immunoassay; Ventricular function **258**, 241
- Very long-chain fatty acids;** Crush syndrome; Hexacosanoic acid; Hexacosenoic acid; Earthquake; Erythrocyte **258**, 125
- Whole blood water;** Plasma water; Hematological and clinicochemical parameters; Health; Disease **258**, 59



